| Literature DB >> 34095565 |
Joelleinsert Ngo Hanna1,2, Vincent de Paul N Nziko3, Fidele Ntie-Kang1,4,5, James A Mbah1, Flavien A A Toze2.
Abstract
A quantitative structure-activity relationship (QSAR) study was conducted using nineteen previously synthesized, and tested 1-aryl-6-hydroxy-1,2,3,4-tetrahydroisoquinolines with proven in vitro activities against Plasmodium falciparum. In order to computationally design and screen potent antimalarial agents, these compounds with known biological activity ranging from 0.697 to 35.978 μM were geometry optimized at the B3LYP/6-311 + G(d,p) level of theory, using the Gaussian 09W software. To calculate the topological differences, the series of the nineteen compounds was superimposed and a hypermolecule obtained with s ¯ = 17 and 20 vertices. Other molecular descriptors were considered in order to build a highly predictive QSAR model. These include the minimal topological differences (MTD), LogP, two dimensional polarity surface area (TDPSA), dipole moment (μ), chemical hardness (η), electrophilicity (ω), potential energy (Ep), electrostatic energy (Eele) and number of rotatable bonds (NRB). By using a training set composed of 15 randomly selected compounds from this series, several QSAR equations were derived. The QSAR equations obtained were then used to attempt to predict the IC50 values of 4 remaining compounds in a test (or validation) set. Ten analogues were proposed by a fragment search of a fragment library containing the pharmacophore model of the active compounds contained in the training set. The most active proposed analogue showed a predicted activity within the lower micromolar range.Entities:
Keywords: Gaussian 09W; In silico design; Malaria; Plasmodium falciparum; QSAR; Screening
Year: 2021 PMID: 34095565 PMCID: PMC8165424 DOI: 10.1016/j.heliyon.2021.e07032
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Chemical structure of compounds under study.
Training and test set used in the QSAR model of anti-malarial agents.
| Training | ||||
|---|---|---|---|---|
| No. | R1 | R2 | R3 | IC50 (μM) |
| 1 | OH | H | 4-chlorophenyl | 0.697 |
| 2 | OH | H | 3,4-dichlorophenyl | 1.343 |
| 3 | OH | H | 3-chlorophenyl | 1.336 |
| 4 | OH | H | 3-methoxyphenyl | 2.530 |
| 5 | OH | H | 2,3-dimethoxyphenyl | 3.126 |
| 6 | OH | H | 2,5-dimethoxyphenyl | 4.276 |
| 7 | OH | H | 4-bromophenyl | 1.581 |
| 8 | OH | H | α,α,α-trifloromethylphenyl | 0.760 |
| 9 | OH | H | biphenyl | 3.006 |
| 10 | OH | H | 2-florophenyl | 9.495 |
| 11 | OH | H | 4-florophenyl | 2.446 |
| 12 | OH | H | 4-chloro-3-nitrophenyl | 6.727 |
| 13 | OH | H | 5-bromo-2-methoxyphenyl | 2.226 |
| 14 | OH | H | 2-hydroxy-5-nitrophenyl | 35.978 |
| 15 | OH | H | 4-methylphenyl | 3.955 |
| Test | ||||
| 16 | OH | H | phenyl | 2.304 |
| 17 | OH | H | 3-nitrophenyl | 1.284 |
| 18 | OH | H | 3-bromophenyl | 3.550 |
| 19 | OH | H | 3-florophenyl | 6.787 |
Figure 2Hypermolecule obtained by superposition of the minimum energy conformations of 19 tetrahydroisoquinoline analogues.
Figure 3Superposition of the minimal energy conformations of the 19 tetrahydroisoquinoline analogues using the MOPAC method from MOE software (Chemical Computing Group Inc, 2010).
Figure 4Geometry optimized structure of the most active 6-hydroxy-1,2,3,4-tetrahydroisoquinoline molecule (1).
Figure 5Scaffold structure and position of R-groups indicates.
Computed molecular descriptors for the training set, used to obtain the QSAR models.
| # | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 3.0 | 73.39 | 32 | 1.8076 | 48.4335 | 45 | 0.0979 | 0.0889 |
| 2 | 3.6 | 78.20 | 32 | 2.9481 | 49.1185 | 29 | 0.0960 | 0.0977 |
| 3 | 3.0 | 73.39 | 32 | 2.2771 | 46.2053 | 45 | 0.0.987 | 0.0874 |
| 4 | 2.2 | 75.05 | 41 | 2.2664 | 57.1440 | 43 | 0.0997 | 0.0743 |
| 5 | 2.3 | 81.52 | 50 | 3.2212 | 78.5233 | 42 | 0.0998 | 0.0717 |
| 6 | 2.1 | 81.52 | 50 | 3.1697 | 71.9990 | 43 | 0.0936 | 0.0698 |
| 7 | 3.2 | 76.21 | 32 | 1.8277 | 46.5528 | 45 | 0.0977 | 0.0893 |
| 8 | 3.3 | 74.56 | 32 | 3.1778 | 50.7209 | 37 | 0.0929 | 0.1064 |
| 9 | 4.2 | 93.73 | 32 | 1.0667 | 70.5986 | 39 | 0.0912 | 0.0975 |
| 10 | 2.8 | 68.81 | 32 | 2.2028 | 45.4703 | 57 | 0.0981 | 0.0857 |
| 11 | 2.5 | 68.81 | 32 | 1.6401 | 45.0356 | 45 | 0.0978 | 0.0878 |
| 12 | 2.4 | 79.54 | 78 | 5.8340 | 64.7792 | 27 | 0.0685 | 0.2127 |
| 13 | 3.0 | 82.68 | 41 | 2.9018 | 60.0532 | 45 | 0.0960 | 0.0857 |
| 14 | 1.2 | 76.52 | 98 | 5.1969 | 58.9141 | 44 | 0.0666 | 0.2035 |
| 15 | 2.7 | 73.63 | 32 | 1.4431 | 46.8571 | 45 | 0.1000 | 0.0763 |
Computed molecular descriptors for the test set, used to validate the QSAR model.
| # | ||||||||
|---|---|---|---|---|---|---|---|---|
| 16 | 2.4 | 68.597 | 32 | 1.0989 | 46.5928 | 61 | 0.1002 | 0.0780 |
| 17 | 1.8 | 74.64 | 78 | 5.4562 | 59.7424 | 41 | 0.0664 | 0.2188 |
| 18 | 3.2 | 76.215 | 32 | 2.2863 | 46.7146 | 45 | 0.0982 | 0.0887 |
| 19 | 2.5 | 68.808 | 32 | 2.1578 | 44.9500 | 45 | 0.0992 | 0.0854 |
Statistical parameters of derived QSAR models.
| QSAR Model | ||||
|---|---|---|---|---|
| Q1 | 0.7434 | 0.2142 | 0.2015 | 9.862 |
| Q2 | 0.7460 | 0.2131 | 0.2131 | 10.778 |
| Q3 | 0.7275 | 0.2207 | 0.2207 | 9.797 |
| Q4 | 0.7434 | 0.2142 | 0.2142 | 10.631 |
Figure 6Cross-validated correlation plots for QSAR models for (A) model 1, and (B) model 2.
Figure 7Cross-validated correlation plots for QSAR models for (A) model 3, and (B) model 4.
Validation of derived QSAR models using residuals.
| Validation Set | RMSE | |||||||
|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| 16 | 0.4043 | 0.4433 | 0.4940 | 0.3860 | 0.2870 | 0.1891 | 0.2131 | 0.1134 |
| 17 | 1.0077 | 1.2516 | 1.2906 | 1.0546 | 0.2234 | 0.2148 | 0.2365 | 0.1248 |
| 18 | -0.2339 | -0.2801 | -0.2649 | -0.2045 | 0.1145 | 0.1236 | 0.2135 | 0.2341 |
| 19 | -0.5693 | -0.5030 | -0.4768 | -0.5621 | 0.1478 | 0.2897 | 0.1278 | 0.2358 |
Figure 8R3 fragments used in the design of library of anti-malarial agents.
Figure 9Chemical structures of predicted activities of six theoretically most potent analogues of 6-hydroxy-1,2,3,4-tetrahydrosioquinoline designed against P. falciparum.
Molecular weights (MW) and computed QSAR descriptors and predicted activities of six theoretically most potent analogs of 6-hydroxy-1,2,3,4-tetrahydrosioquinoline designed against P. falciparum.
| Analog | LogP | MW | NRB | MTD | TDPSA | Ep | η | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TIQ-02 | 2.2 | 255.31 | 2 | 43 | 41 | 55.064 | 0.827 | 0.068 | -0.446 | -15.341 | -1.400 | -0.406 | 2.796 | 2.196 | 25.132 | 2.546 |
| TIQ-03 | 2.1 | 260.72 | 1 | 45 | 45 | 34.274 | 0.971 | 0.459 | -0.576 | -17.321 | -6.520 | -0.556 | 3.771 | 2.092 | 33.113 | 3.600 |
| TIQ-04 | 3.1 | 298.77 | 1 | 37 | 48 | 45.084 | 0.372 | 0.152 | -0.538 | -8.255 | -2.346 | -0.509 | 3.454 | 1.800 | 221.685 | 3.229 |
| TIQ-08 | 1.7 | 260.72 | 1 | 45 | 45 | 75.038 | 0.594 | 0.418 | -0.564 | -12.070 | -6.439 | -0.505 | 3.668 | 1.175 | 27.459 | 3.196 |
| TIQ-09 | 2.3 | 249.69 | 1 | 43 | 45 | 92.87 | 0.547 | 0.068 | -0.597 | -11.458 | -1.914 | -0.520 | 3.958 | 2.868 | 82.004 | 3.311 |
| TIQ-10 | 2.1 | 248.71 | 1 | 43 | 48 | 38.495 | 0.408 | 0.170 | -0.592 | -8.928 | -2.565 | -0.569 | 3.906 | 8.466 | 367.120 | 3.707 |
P is defined as the n-octanol/water partition coefficient.
MW is the molecular weight of the compound.
NRB is the number of rotatable bonds and TDPSA is the two dimensional polarity surface area (logp P, MW, NRB, 2DPSA were calculated using BROOD [12]).
Computed ADMET-related parameters for newly designed analogs.
| Hits | #stars | MW | SASA | FOSA | Volume | NRB | HBdon | HBacc | logPo/w | logSwat | logKhsa | logBB | BIPcaco | #metab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TIQ-02 | 0 | 255.32 | 501.228 | 197.373 | 858.666 | 2 | 2 | 3 | 2.423 | -2.642 | 0.21 | 0.172 | 466.401 | 4 |
| TIQ-03 | 0 | 260.72 | 488.775 | 110.363 | 821.025 | 1 | 2 | 2.5 | 2.512 | -3.019 | 0.234 | 0.258 | 327.856 | 4 |
| TIQ-04 | 0 | 298.77 | 523.246 | 108.051 | 903.608 | 1 | 3 | 2.25 | 2.892 | -3.412 | 0.365 | 0.216 | 306.337 | 3 |
| TIQ-08 | 0 | 260.72 | 489.188 | 108.839 | 822.53 | 1 | 2 | 3.25 | 2.315 | -2.853 | 0.132 | 0.324 | 384.408 | 4 |
| TIQ-09 | 0 | 249.69 | 466.843 | 117.788 | 775.681 | 1 | 2 | 2.000 | 2.497 | -2.748 | 0.185 | 0.405 | 458.461 | 4 |
| TIQ-10 | 1 | 248.71 | 473.853 | 116.618 | 785.775 | 1 | 3 | 1.5∗ | 2.285 | -2.684 | 0.139 | 0.172 | 263.105 | 3 |
MW: molecular weight in Da (range for 95% of drug: 130-725Da).
SASA: total solvent-accessible molecular surface, in Hydrophobic portion of the solvent-accessible molecular surface, in Å2 (range for 95% of drug: 300-750Å2).
Volume: total volume of molecule enclose by solvent-accessible molecular surface, in Å3.
NRB: number of rotatable bonds (range for 95% of drug: 0–15).
HBdon: number of hydrogen bonds donated by the molecule (range for 95% of drug: 0–6).
HBacc: number of hydrogen bonds accepted by the molecule (range for 95% of drug: 2–20).
LogPo/w: logarithm of partition coefficient between n-octanol and water phases (range for 95% of drug: -2 to 6).
LogSwat: logarithm of aqueous solubility (range for 95% of drug: -6.0 to 0.5).
LogKhsa: logarithm of predicted binding constant to human serum albumin (range for 95% of drug: -1.5 to 1.2).
LogBB: logarithm of predicted blood/brain barrier partition coefficient (range for 95% of drug: -3.0 to 1.0).
BIPcaco: predicted apparent caco-2 cell membrane permeability in Boehringer-ingelheim scale in nm/s(range for 95% of drug: <5 low, >100 high).
#metab: number of likely metabolic reactions.